Kairos Pharma, Ltd.
KAPA
$1.66
$0.000.00%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.51M | 3.67M | 3.44M | 3.83M | 3.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.96M | 6.00M | 5.57M | 5.60M | 4.55M |
| Operating Income | -5.96M | -6.00M | -5.57M | -5.60M | -4.55M |
| Income Before Tax | -5.81M | -5.84M | -5.45M | -5.06M | -4.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.81 | -5.84 | -5.45 | -5.06 | -4.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.81M | -5.84M | -5.45M | -5.06M | -4.71M |
| EBIT | -5.96M | -6.00M | -5.57M | -5.60M | -4.55M |
| EBITDA | -5.82M | -5.84M | -5.41M | -5.44M | -4.39M |
| EPS Basic | -1.95 | -2.07 | -2.08 | -2.13 | -2.32 |
| Normalized Basic EPS | -1.22 | -1.30 | -1.30 | -1.53 | -1.65 |
| EPS Diluted | -1.95 | -2.07 | -2.08 | -2.13 | -2.32 |
| Normalized Diluted EPS | -1.22 | -1.30 | -1.30 | -1.53 | -1.65 |
| Average Basic Shares Outstanding | 11.93M | 11.32M | 10.59M | 9.53M | 8.20M |
| Average Diluted Shares Outstanding | 11.93M | 11.32M | 10.59M | 9.53M | 8.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |